

Amendments to the Specification:

Please replace the paragraph bridging pages 3 and 4, with the following amended paragraph:

The thymus is arguably the major organ in the immune system because it is the primary site of production of T lymphocytes. Its role is to attract appropriate bone marrow-derived precursor cells from the blood, and induce their commitment to the T cell lineage including the gene rearrangements necessary for the production of the T cell receptor for antigen (TCR). Associated with this is a remarkable degree of cell division to expand the number of T cells and hence ~~increase~~ increases the likelihood that every foreign antigen will be recognized and eliminated. A unique feature of T cell recognition of antigen, however, is that unlike B cells, the TCR only recognizes peptide fragments physically associated with MHC molecules; normally this is self MHC and this ability is selected for in the thymus. This process is called positive selection and is an exclusive feature of cortical epithelial cells. If the TCR fails to bind to the self MHC/peptide complexes, the T cell dies by "neglect" – it needs some degree of signalling through the TCR for its continued maturation.

Please replace the paragraph on page 10, lines 2-8, with the following amended paragraph:

The present inventors have demonstrated that thymic atrophy (~~aged-induced~~ age-induced, or as a consequence of conditions such as chemotherapy or radiotherapy) can be profoundly reversed by inhibition of sex steroid production, with virtually complete restoration of thymic structure and function. The present inventors have also found that the basis for this thymus regeneration is in part due to the initial expansion of precursor ~~cells which~~ cells, which are derived both intrathymically and via the blood

stream. This finding suggests that it is possible to seed the thymus with exogenous haemopoietic stem cells (~~HSC~~) which (HSC), which have been injected into the subject.

Please replace the paragraph on page 10, lines 9-13, with the following amended paragraph:

The ability to seed the thymus with genetically modified or exogenous HSC by disrupting sex steroid signalling steroid-signaling to the thymus, means that gene therapy in the HSC may be used more efficiently to treat T cell (and myeloid cells which develop in the thymus) disorders. HSC stem cell therapy has met with little or no success to date because the thymus is dormant and incapable of taking up many if any HSC, with T cell production less than 1% of normal levels.

Please replace the paragraph on page 11, lines 8-14, with the following amended paragraph:

In one aspect the present disclosure provides ~~a improving an improvement in~~ the vaccine response to a vaccine antigen (e.g., that of an agent), the method comprising disrupting sex steroid mediated steroid-mediated signaling to the thymus in the patient. In one embodiment, GnRH analogs (agonist and antagonists thereto) are used to disrupt sex steroid-mediated signaling to the thymus. In another embodiment, GnRH analogs directly stimulate (i.e., directly increase the functional activity of) the thymus, bone marrow, and pre-existing cells of the immune system, such as T cells, B cells, and dendritic cells (DC).

Please replace the paragraph on page 11, lines 15-18, with the following amended paragraph:

The methods of this invention rely on blocking sex steroid-mediated steroid-mediated signaling to the thymus. In one embodiment, chemical castration is used. In another embodiment surgical castration is used. Castration reverses the state of the thymus to its pre-pubertal state, thereby reactivating it.

Please replace the paragraph on page 11, lines 19-22, with the following amended paragraph:

In a particular embodiment sex steroid-mediated steroid-mediated signaling to the thymus is blocked by the administration of agonists or antagonists of LHRH, anti-estrogen antibodies, anti-androgen antibodies, passive (antibody) or active (antigen) anti-LHRH vaccinations, or combinations thereof ("blockers").

Please replace the paragraph on page 12, lines 5-11, with the following amended paragraph:

In cases where the subject is infected with HIV, the HSC may be genetically modified such that they and their progeny, in particular T cells, macrophages and dendritic cells, are resistant to infection ~~and/or~~ and/or destruction with the HIV virus. The genetic modification may involve introduction into the HSC of one or more nucleic acid molecules which prevent viral replication, assembly and/or infection. The nucleic acid molecule may be a gene which ~~encodes~~ encodes an antiviral protein, an antisense construct, a ribozyme, a dsRNA and a catalytic nucleic acid molecule.

Please replace the paragraph on page 12, lines 14-20, with the following amended paragraph:

In certain embodiments, inhibition of sex steroid production is achieved by either castration or administration of a sex steroid analogue(s) analogs. Non-limiting sex steroid analogues analogs include eulexin, goserelin, leuprorelin, dioxalan derivatives such as triptorelin, meterelin, buserelin, histrelin, nafarelin, lutrelin, leuprorelin, and luteinizing hormone-releasing hormone analogues analogs. In some embodiments, the sex steroid analogue analog is an analogue analog of luteinizing hormone-releasing hormone. In certain embodiments, the luteinizing hormone-releasing hormone analogue analog is deslorelin.

Please replace the paragraph on page 31, lines 3-7, with the following amended paragraph:

Methods of detecting new T cells in the blood are known in the art. For instance, one method of T cell detection is by determining the existence of T cell receptor excision circles (TREC's), which are formed when the TCR is being formed and are lost in the cell after it divides. Hence, TREC's are only found in new (naïve) T cells. TREC levels are one indicator of thymic function in humans. These and other methods are described in detail in ~~WO/00 230,256~~ WO 02/030256, which is herein incorporated by reference.

Please replace the paragraph bridging pages 31 and 32, with the following amended paragraph:

Examples of infectious viruses include: Retroviridae (*e.g.*, human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV), or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (*e.g.*, polio

viruses, hepatitis A virus; enteroviruses, human coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses); Coronaviridae (e.g., coronaviruses, severe acute respiratory syndrome (SARS) virus); Rhabdoviridae (e.g., vesicular stomatitis viruses, rabies viruses); Filoviridae (e.g., ebola viruses); Paramyxoviridae (e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza viruses); Bunyaviridae (Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses); ~~Arena-viridae~~ Arenaviridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, orbiviruses and rotaviruses); Birnaviridae; Hepadnaviridae (e.g., Hepatitis B virus); Parvoviridae (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae (e.g., herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes viruses); Poxviridae (e.g., variola viruses, vaccinia viruses, pox viruses); and Iridoviridae (e.g., African swine fever virus); and unclassified viruses (e.g., the etiological agents of Spongiform encephalopathies, the agent of delta hepatites (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1=internally transmitted; class 2=parenterally transmitted (i.e., Hepatitis C); Norwalk and related viruses, and astroviruses).

Please replace the paragraph on page 32, lines 18-28, with the following amended paragraph:

Examples of infectious bacteria include: *Helicobacter pyloris* *Helicobacter pylori*, *Borelia burgdorferi*, *Legionella pneumophilia*, *Mycobacteria* sporozoites (sp.) (e.g. *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. kansaii*, *M. gordonae*), *Staphylococcus aureus*,

Neisseria gonorrhoeae, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A *Streptococcus*), *Streptococcus agalactiae* (Group B *Streptococcus*), *Streptococcus* (viridans group), *Streptococcus faecalis*, *Streptococcus bovis*, *Streptococcus* (anaerobic sps.), *Streptococcus pneumoniae*, pathogenic *Campylobacter* sp., *Enterococcus* sp., *Haemophilus influenzae*, *Bacillus anthracis* *Bacillus anthracis*, *Corynebacterium diphtheriae*, *Corynebacterium* sp., *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasturella multocida*, *Bacteroides* sp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenue*, *Leptospira*, and *Actinomyces israelii*.

Please replace the paragraph at page 35, lines 17-30, with the following amended paragraph:

____ Administration may be by any method which delivers the ~~sex steroid ablating sex steroid-ablating~~ agent into the body. Thus, the ~~sex steroid ablating steroid-ablating~~ agent ~~may be be~~ ~~may be~~ administered, in accordance with the invention, by any route including, without limitation, intravenous, subdermal, subcutaneous, intramuscular, topical, and oral routes of administration. One non-limiting example of administration of a ~~sex steroid ablating steroid-ablating~~ agent is a subcutaneous/intradermal injection of a "slow-release" depot of GnRH agonist (e.g., one, three, or four month Lupron® injections) or a subcutaneous/intradermal injection of a "slow-release" GnRH-containing implant (e.g., one or three month Zoladex®, e.g., 3.6 mg or 10.8 mg implant). These could also be given ~~intramuscularly~~ ~~intramuscularly~~ (i.m.), intravenously (i.v.) or orally, depending on the appropriate formulation. Another example is by subcutaneous injection of a "depot" or "impregnated implant" containing, for example, about 30 mg of Lupron® (e.g., ~~Lupron Depot®~~, leuprolide acetate for depot

~~suspension) TAP Pharmaceuticals Products, Inc., Lake Forest, IL (e.g., Lupron Depot®, (leuprolide acetate for depot suspension) TAP Pharmaceutical Products, Inc., Lake Forest, IL).~~ A 30 mg Lupron® injection is sufficient for four months of sex steroid ablation to allow the thymus to rejuvenate and export new naïve T cells into the blood stream.

Please replace the paragraph at page 36, lines 1-25, with the following amended paragraph:

In some embodiments, sex steroid ablation or inhibition of ~~sex-steroid signaling~~ steroid-signaling is accomplished by administering an anti-androgen such as an androgen blocker (e.g., bicalutamide, trade names Cosudex® or Casodex®, AstraZeneca, ~~Auckland~~ Auckland, NZ), either alone or in combination with an LHRH analog or any other method of castration. Sex steroid ablation or interruption of ~~sex steroid signaling~~ steroid-signaling may also be accomplished by administering cyproterone acetate (trade name, Androcor®, ~~Shering Schering~~ AG, Germany; e.g., 10-1000 mg, 100 mg bd or tds, or 300 mg IM weekly, a 17-hydroxyprogesterone acetate, which acts as a progestin, either alone or in combination with an LHRH analog or any other method of castration. Alternatively, other anti-androgens may be used (e.g., antifungal agents of the imidazole class, such as ~~liarozole (Liazol® e.g., 150 mg/day, an aromatase inhibitor)~~ liarozole (Liazol®, e.g., 150 mg/day, an aromatase inhibitor) and ketoconazole, bicalutamide (trade name Cosudex® or Casodex®, 5-500 mg, e.g., 50 mg po QID), flutamide (trade names Euflex® and Eulexin®, ~~Shering Schering~~ Plough Corp, N.J.; 50-500 mg e.g., 250 or 750 po QID), megestrol acetate (Megace®) e.g., 480-840 mg/day or nilutamide (trade names Anandron®, and Nilandron®, Roussel, France e.g., orally, 150-300 mg/day)). Antiandrogens are often important in therapy, since they are commonly utilized to address flare by GnRH analogs. Some antiandrogens act by

inhibiting androgen receptor translocation, which interrupts negative feedback resulting in increased testosterone levels and minimal loss of libido/potency. Another class of anti-androgens useful in the present invention are the selective androgen receptor modulators (SARMS) (*e.g.*, quinoline derivatives, bicalutamide (trade name Cosudex® or Casodex®, ICI Pharmaceuticals, England *e.g.*, orally, 50 mg/day), and flutamide (trade name Eulexin®, *e.g.*, orally, 250 mg/day)). Other well known anti-androgens include 5 alpha reductase inhibitors (*e.g.*, ~~dutasteride, (e.g., 0.5 mg/day)~~ dutasteride, (e.g., 0.5 mg/day) which inhibits both 5 alpha reductase isoenzymes and results in greater and more rapid DHT suppression; finasteride (trade name Proscar®; ~~0.5-500mg, e.g., 0.5-500 mg, e.g., 5 mg po daily~~), which inhibits ~~5alpha~~ 5 alpha reductase 2 and consequent DHT production, but has little or no effect on testosterone or ~~LH levels); LH levels).~~ LH levels); LH levels).

Please replace the paragraph bridging pages 36 and 37, with the following amended paragraph:

In other embodiments, sex steroid ablation or inhibition of ~~sex steroid signaling~~ steroid-signaling is accomplished by administering anti-estrogens either alone or in combination with an LHRH analog or any other method of castration. Some anti-estrogens (*e.g.*, anastrozole (trade name Arimidex®), and fulvestrant (trade name Faslodex®) act by binding the estrogen receptor (ER) with high affinity similar to estradiol and consequently inhibiting estrogen from binding. Faslodex® binding also triggers conformational change to the receptor and down-regulation of estrogen receptors, without significant change in FSH or LH levels. Other non-limiting examples of anti-estrogens are tamoxifen (trade name Nolvadex®); ~~Clomiphene (trade name Clomid®) e.g., 50-250mg/day~~ Clomiphene (trade name Clomid®) e.g., 50-250 mg/day, a

non-steroidal ER ligand with mixed agonist/antagonist properties, which stimulates release of gonadotrophins; Fulvestrant (trade name Faslodex®; ~~10-1000 mg~~ 10-1000 mg, e.g., ~~250 mg~~ 250 mg IM monthly); diethylstilbestrol ((DES), trade name Stilphostrol®) e.g., ~~1-3 mg/day~~ e.g., 1-3 mg/day, which shows estrogenic activity similar to, but greater than, that of estrone, and is therefore considered an estrogen agonist, but binds both androgen and estrogen receptors to induce feedback inhibition on FSH and LH production by the pituitary, diethylstilbestrol diphosphate ~~e.g., 50 to 200 mg/day~~ e.g., 50 to 200 mg/day; as well as ~~danazol~~, droloxifene ~~danazol~~, droloxifene, and iodoxyfene, which each act as antagonists. Another class of anti-estrogens which may be used either alone or in combination with other methods of castration, are the selective estrogen receptor modulators (SERMS) (e.g., toremifene (trade name Fareston®, ~~5-1000 mg~~ 5-1000 mg, e.g., ~~60 mg~~ 60 mg po QID), raloxofene (trade name Evista®), and tamoxifen (trade name Nolvadex®, ~~1-1000 mg~~ 1-1000 mg, e.g., ~~20 mg~~ 20 mg po bd), which behaves as an agonist at estrogen receptors in bone and the cardiovascular system, and as an antagonist at estrogen receptors in the mammary gland). Estrogen receptor downregulators (ERDs) (e.g., tamoxifen (trade name, Nolvadex®)) may also be used in the present invention.

Please replace the paragraph bridging pages 37 and 38, with the following amended paragraph:

Other non-limiting examples of methods of inhibiting sex ~~steroid signalling~~ steroid-signaling which may be used either alone or in combination with other methods of castration, include aromatase inhibitors and other adrenal gland blockers (e.g., Aminoglutethimide, formestane, vorazole, exemestane, anastrozole (trade name Arimidex®, ~~0.1-100 mg~~ 0.1-100 mg, e.g., 1 mg po QID), which lowers estradiol and

increases LH and testosterone), letrozole (trade name Femara®, 0.2-500 mg, e.g., ~~2.5mg~~
~~2.5 mg~~ po QID), and exemestane (~~trade name Aromasin®~~)~~1-2000 mg, e.g., 25mg/day~~
(~~trade name Aromasin®~~) ~~1-2000 mg, e.g., 25 mg/day~~; aldosterone antagonists (e.g., spironolactone (trade name, Aldactone®) e.g., ~~100 to 400mg/day~~ ~~100 to 400 mg/day~~), which blocks the androgen cytochrome P-450 receptor;) and eplerenone, a selective aldosterone-receptor antagonist) antiprogestogens (e.g., medroxyprogesterone acetate, e.g. ~~5mg/day~~ e.g., ~~5 mg/day~~, which inhibits testosterone syntheses and LH synthesis); and progestins and anti-progestins such as the selective progesterone response modulators (SPRM) (e.g., megestrol acetate e.g., ~~160mg/day~~ e.g., ~~160 mg/day~~, mifepristone (RU 486, Mifeprex®, e.g. ~~200mg/day~~ e.g., ~~200 mg/day~~); and other compounds with estrogen/antiestrogenic activity, (e.g., phytoestrogens, flavones, isoflavones and coumestan derivatives, lignans, and industrial compounds with phenolic ring (e.g., DDT)). Also, anti-GnRH vaccines (see, e.g., Hsu *et al.*, (2000) *Cancer Res.* 60:3701; Talwar, (1999) *Immunol. Rev.* 171:173-92), or any other pharmaceutical which mimics the effects produced by the aforementioned drugs, may also be used. In addition, steroid receptor based modulators, which may be targeted to be thymic specific, may also be developed and used. Many of these mechanisms of inhibiting sex steroid signaling ~~steroid-signaling~~ are well known. Each ~~drugs~~ drug may also be used in modified form, such as acetates, citrates and other salts thereof, which are well known to those in the art.

Please replace the paragraph on page 38, lines 9-14, with the following amended paragraph:

Because of the complex and interwoven feedback mechanisms of the hormonal system, administration of sex steroids may result in inhibition of sex ~~steroid signalling~~

steroid-signaling. For example, estradiol decreases gonadotropin production and sensitivity to GnRH action. However, higher levels of estradiol result in gonadotropin surge. Likewise, progesterone influences frequency and amount of LH release. In men, testosterone inhibits gonadotropin production. Estrogen administered to men decreases LH and testosterone, and anti-estrogen increases LH.

Please replace the paragraph on page 38, lines 19-23, with the following amended paragraph:

In some embodiments, the sex ~~steroid-mediated~~ steroid-mediated signaling to the thymus is disrupted by administration of gonadotrophin-releasing hormone (GnRH) or an analog thereof. GnRH is a hypothalamic decapeptide that stimulates the secretion of the pituitary gonadotropins, leutinizing hormone (LH) and follicle-stimulating hormone (FSH). Thus, GnRH, e.g., in the form of Synarel or Lupron, will suppress the pituitary gland and stop the production of FSH and LH.

Please replace the paragraph bridging pages 38 and 39, with the following amended paragraph:

In some embodiments, the sex ~~steroid-mediated~~ steroid-mediated signaling to the thymus is disrupted by administration of a sex steroid analog, such as an analog of leutinizing hormone-releasing hormone (LHRH). ~~Sex steroid analogs and their use in therapies and chemical castration are well known.~~ Sex steroid analogs are commercially known and their use in therapies and chemical castration are well known. Such analogs include, but are not limited to, the following agonists of the LHRH

receptor (LHRH-R): buserelin (*e.g.*, buserelin acetate, trade names Suprefact® (*e.g.*, 0.5-0.2 mg s.c./day), Suprefact Depot®, and Suprefact® Nasal Spray (*e.g.*, 2 µg per nostril, every 8 hrs.), Hoechst, also described in U.S. Patent Nos. 4,003,884, 4,118,483, and 4,275,001); Cystorelin® (*e.g.*, gonadorelin diacetate tetrahydrate, Hoechst); deslorelin (*e.g.*, ~~desorelin~~ deslorelin acetate, Deslorell®, Balance Pharmaceuticals); gonadorelin (*e.g.*, gonadorelin hydrochloride, trade name Factrel® (100 µg i.v. or s.c.), Ayerst Laboratories); goserelin (goserelin acetate, trade name Zoladex®, AstraZeneca, ~~Auckland~~ Auckland, NZ, also described in U.S. Patent Nos. 4,100,274 and 4,128,638; GB 9112859 and GB 9112825); histrelin (*e.g.*, ~~histerelin acetate~~ histrelin acetate, Supprelin®, (~~s.c., 10 µg/kg/day~~ s.c., 10 µg/kg/day), Ortho, also described in EP 217659); leuprolide (leuprolide acetate, trade name Lupron® or Lupron Depot®, Abbott/TAP, Lake Forest, IL, also described in U.S. Patent Nos. 4,490,291, 3,972,859, 4,008,209, 4,992,421, and 4,005,063; DE 2509783); leuprorelin (*e.g.*, ~~leuprorelin~~ leuprorelin acetate, trade name Prostap SR® (*e.g.*, single 3.75 mg dose s.c. or i.m./month), Prostap3® (*e.g.*, single ~~11.25 mg~~ 11.25 mg dose s.c. every 3 months), Wyeth, USA, also described in Plosker *et al.*, (1994) Drugs 48:930); lutrelin (Wyeth, USA, also described in U.S. Patent No. 4,089,946); Meterelin® (*e.g.*, Avorelina (*e.g.*, 10-15 mg slow-release formulation), also described in ~~EP 23904 and~~ WO 91/18016); nafarelin (*e.g.*, trade name Synarel® (i.n. 200-1800 µg/day), Syntex, also described in U.S. Patent No. 4,234,571; ~~WO 93/15722~~ WO 93/15722; and ~~EP 52510~~ EP0052510); and triptorelin (*e.g.*, triptorelin pamoate; trade names Trelstar LA® (11.25 mg over 3 months), Trelstar LA Debioclip® (pre-filled, single dose delivery), LA Trelstar Depot® (3.75 mg over one month), and Decapeptyl®, Debiopharm S.A., ~~Switzerland~~ Switzerland, also described in U.S. Patent Nos. 4,010,125, 4,018,726, 4,024,121, and 5,258,492; EP 364819). LHRH analogs also include, but are not limited to, the following antagonists of the LHRH-R: abarelix (trade name Plenaxis™ (*e.g.*, 100 mg i.m. on days 1, 15 and 29, then every 4 weeks thereafter), Praecis

Pharmaceuticals, Inc., Cambridge, MA) and cetrorelix (*e.g.*, cetrorelix acetate, trade name Cetrotide™ (*e.g.*, 0.25 or 3 mg s.c.), Zentaris, Frankfurt, Germany). Additional sex steroid analogs include Eulexin® (*e.g.*, flutamide (*e.g.*, 2 capsules 2x/day, total 750 mg/day), Schering-Plough Corp., also described in FR 7923545, WO 86/01105 and PT 100899), and dioxane derivatives (*e.g.*, those described in EP 413209), and other LHRH analogues analogs such as are described in EP 181236, U.S. Patent Nos. 4,608,251, 4,656,247, 4,642,332, 4,010,149, 3,992,365, and 4,010,149. Combinations of agonists, combinations of antagonists, and combinations of agonists and antagonists are also included. One non-limiting analog of the invention is deslorelin (described in U.S. Patent No. 4,218,439). For a more extensive list, of list of analogs, see Vickery *et al.* (1984) LHRH and Its Analogs: Contraceptive & Therapeutic Applications (Vickery *et al.*, eds.) MTP Press Ltd., Lancaster, PA. Each analog may also be used in modified form, such as acetates, citrates and other salts thereof, which are well known to those in the art.

Please replace the paragraph bridging pages 43 and 44, with the following amended paragraph:

The intracellular receptors are members of the nuclear receptor superfamily. They are located in the cytoplasm of the cell and are transported to the nucleus after binding with the sex steroid hormone where they alter the transcription of specific genes. Receptors for the sex steroid hormones exist in several forms. Well known in the literature are two forms of the progesterone receptor, PRA and PRB, and three forms of the estrogen receptor, ER α , ER β 1 and ER β 2. Transcription of genes in response to the binding of the sex steroid hormone receptor to the steroid response element in the promoter region of the gene can be modified in a number of ways. Co-activators and

co-repressors exist within the nucleus of the target cell that can modify binding of the steroid-receptor complex to the DNA and thereby effect transcription. The identity of many of these co-activators and co-repressors are known and methods of modifying their actions on steroid receptors are the topic of current research. Examples of the transcription factors involved in sex steroid hormone action are NF-1, SP1, ~~Oct-1 and Oct-1 and~~ TFIID. These co-regulators are required for the full action of the steroids. Methods of modifying the actions of these nuclear regulators could involve the balance between activator and repressor by the use of antagonists or through control of expression of the genes encoding the regulators.

Please replace the paragraph at page 49, lines 7-11, with the following amended paragraph:

____ Those skilled in the art would be able to develop suitable anti-HIV constructs for use in the present invention. Indeed, a number of anti-HIV antisense constructs and ribozymes have already been developed and are described, for example; in U.S. Patent No. 5,811,275, U.S. Patent No. 5,741,706, PCT Publication No. WO 94/26877, Australian Patent Application No. 56394/94 and U.S. Patent No. 5,144,019.

Please replace the paragraph at page 58, lines 20-26, with the following amended paragraph:

Within 3-4 weeks of the start of blockage of sex steroid mediated steroid-mediated signaling (approximately 2-3 weeks after the initiation of LHRH treatment), the first new T cells are present in the blood stream. Full development of the T cell pool, however, may take 3-4 months. Vaccination may begin soon after the appearance

of the newly produced naïve cells; however, the wait may be 4-6 weeks after the initiation of LHRH therapy to begin vaccination, when enough new T cells to create a strong response will have been produced and will have undergone any necessary post-thymic ~~maturity~~ maturation.

Please replace the paragraph at page 60, lines 9-14, with the following amended paragraph:

Animals. CBA/CAH and C57Bl6/J male mice were obtained from Central Animal Services, Monash University and were housed under conventional conditions. C57Bl6/J Ly5.1⁺ were obtained from the ~~Central Animal Services Monash University~~ Central Animal Services, Monash University, the ~~Walter and~~ Walter and Eliza Hall Institute for Medical Research (Parkville, Victoria) and the A.R.C. (Perth Western Australia) and were housed under conventional conditions. Ages ranged from 4-6 weeks to 26 months of age and are indicated where relevant.

Please replace the paragraph at page 65, lines 14-21, with the following amended paragraph:

The DN subpopulation, in addition to the thymocyte precursors, contains ~~αβTCR+CD4-CD8-~~ αβTCR+CD4-CD8- thymocytes, which are thought to have downregulated both co-receptors at the transition to SP cells (Godfrey & Zlotnik, 1993). By gating on these mature cells, it was possible to analyze the true TN compartment (CD3-CD4-CD8-) and their subpopulations expressing CD44 and CD25. Figures 5H, 5I, 5J, and 5K illustrate the extent of proliferation within each subset of TN cells in young, old and castrated mice. This showed a significant ($p<0.001$) decrease in proliferation of

the TN1 subset ($CD44^+CD25^-CD3^-CD4^-CD8^-$), from ~10% 10% in the normal young to around 2% at 18 months of age (Fig. 5H) which was restored by 1 week post-castration.

Please replace the paragraph at page 67, lines 3-8, with the following amended paragraph:

The thymic extracellular matrix, containing important structural and cellular adhesion molecules such as collagen, laminin and fibrinogen, was detected by the mAb MTS 16. Scattered throughout the normal young thymus, the nature of MTS 16 expression ~~becomes~~ became more widespread and interconnected in the aged thymus. Expression of MTS 16 was increased further at 2 weeks post-castration while at 4 weeks post-castration, this expression ~~is~~ was representative of the situation in the 2 month thymus (data not shown).

Please replace the paragraph at page 74, lines 4-11, with the following amended paragraph:

The above findings indicate a defect in the thymic epithelium ~~rendering it rendering it~~ incapable of providing the developing thymocytes with the necessary stimulus ~~for development for development~~. However, the symbiotic nature of the ~~thymic epithelium thymic epithelium~~ and thymocytes makes it difficult to ascertain the exact pathway of destruction by the sex steroid influences. The medullary epithelium requires cortical T cells for its proper development and maintenance. Thus, if this population is ~~diminished, the diminished, the~~ medullary thymocytes may not receive adequate signals for development. This particularly seems to affect the $CD8^+$

population. IRF^{-/-} mice show a decreased number of CD8⁺ T cells. It would therefore, be interesting to determine the proliferative capacity of these cells.

Please replace the paragraph bridging pages 83 and 84, with the following amended paragraph:

In noncastrated mice, there was a profound decrease in thymocyte number over the 4 week time period, with little or no evidence of regeneration (Fig. 21A). In the castrated group, however, by two weeks there was already extensive thymopoiesis which by four weeks had returned to control levels, being 10 fold higher than in noncastrated mice. Flow cytometric analysis of the thymii with respect to CD45.2 (donor-derived antigen) demonstrated that no ~~donor-derived~~ donor-derived cells were detectable in the noncastrated group at 4 weeks, but remarkably, virtually all the thymocytes in the castrated mice were donor-derived at this time point (Fig. 21B). Given this extensive enhancement of thymopoiesis from donor-derived haemopoietic precursors, it was important to determine whether T cell differentiation had proceeded normally. CD4, CD8 and TCR defined subsets were ~~analysed~~ analyzed by flow cytometry. There were no proportional differences in thymocytes subset proportions 2 weeks after reconstitution (Fig. 22). This observation was not possible at 4 weeks, because the noncastrated mice were not reconstituted with donor-derived cells. However, at this time point the thymocyte proportions in castrated mice appear normal.

Please replace the paragraph at page 89, lines 6-13, with the following amended paragraph:

The patient was given sex steroid ablation therapy in the form of delivery of an LHRH agonist. This was given in the form of either Leucrin (depot injection; ~~22.5mg~~

22.5 mg) or Zoladex (implant; 10.8 mg), either one as a single dose effective for 3 months. This was effective in reducing sex steroid levels sufficiently to reactivate the thymus. In other words, the serum levels of sex steroids were undetectable (castrate; <0.5ng/ml <0.5 ng/ml blood). In some cases it is also necessary to deliver a suppresser of adrenal gland production of sex steroids. Caused (5mg/day 5 mg/day) as one tablet per day may be delivered for the duration of the sex steroid ablation therapy. Adrenal gland production of sex steroids makes up around 10-15% of a human's steroids.

Please replace the paragraph at page 89, lines 14-19, with the following amended paragraph:

Reduction of sex steroids in the blood to minimal values took about 1-3 weeks; concordant with this was the reactivation of the thymus. In some cases it is necessary to extend the treatment to a second 3 month injection/implant. The thymic expansion may be increased by simultaneous enhancement of blood HSC either as an allogeneic donor (in the case of grafts of foreign tissue) or autologous HSC (by injecting the host with G-CSF to mobilize these HSC from the bone marrow to the thymus thymus).

Please replace the paragraph bridging pages 90 and 91, with the following amended paragraph:

Where practical, the level of hematopoietic stem cells (HSC) in the donor blood is enhanced by injecting into the donor granulocyte-colony stimulating factor (G-CSF) at 10 μ g/kg 10 μ g/kg for 2-5 days prior to cell collection (e.g., one or two injections of 10 μ g/kg per day for each of 2-5 days). CD34 $^{+}$ donor cells are purified from the donor blood or bone marrow, such as by using a flow cytometer or immunomagnetic beading.

Antibodies that specifically bind to human CD34 are commercially available (from, e.g., Research Diagnostics Inc., Flanders, NJ). Donor-derived HSC are identified by flow cytometry as being CD34⁺. These CD34⁺ HSC may also be expanded by in vitro culture using feeder cells (e.g., fibroblasts), growth factors such as stem cell factor (SCF), and LIF to prevent differentiation into specific cell types. At approximately 3-4 weeks post LHRH agonist delivery (*i.e.*, just before or at the time the thymus begins to regenerate) the patient is injected with the donor HSC, optimally at a dose of about 2-4 × 10⁶ cells/kg. G-CSF may also be injected into the recipient to assist in expansion of the donor HSC. If this timing schedule is not possible because of the critical nature of clinical condition, the HSC could be administered at the same time as the GnRH. It may be necessary to give a second dose of HSC 2-3 weeks later to assist in the thymic regrowth and the development of donor DC (particularly in the thymus). Once the HSC have ~~engraftment~~ engrafted (*i.e.*, have incorporated into the bone marrow and thymus), the effects should be permanent since the HSC are self-renewing.

Please replace the paragraph bridging pages 95 and 96, with the following amended paragraph:

Enzyme-linked immunosorbent immunosorbent assays. At various time periods pre- and post-immunization (or pre- and post- infection), mice from each group are bled, and individual mouse serum is tested using standard quantitative quantitative enzyme-linked immunosorbent immunosorbent assays (ELISA) to assess anti-HA or - NP specific IgG levels in the serum. IgG1 and IgG2a levels may optionally be tested, which are known to correlate with Th2 and Th1-type antibody responses, respectively. Briefly, sucrose gradient-purified A/PR/8/34 influenza virus is disrupted in flu lysis buffer (0.05 M Tris-HCL (pH 7.5-7.8), 0.5% ~~Triton X-100~~ Triton X-100, 0.6 M KCl) for 5

minutes at room temperature. Ninety-six well ELISA plates (Corning, Corning, NY) are coated with 200 HAU influenza in carbonate buffer (0.8 g Na₂CO₃, 1.47 g NaHCO₃, 500 ml ddH₂O, pH to 9.6) and incubated overnight 4°C. Plates are blocked with 200 µl of 1% BSA in PBS for 1 hour at 37°C and washed 5 times with PBS/0.025% Tween-20. Samples and standards are diluted in Standard Dilution Buffer (SDB) (0.5% BSA in PBS), added to microtiter plates at 50 µl per well, and incubated at 37°C for 90 min. Following binding of antibody, plates are washed 5 times. Fifty microliters of HRP-labeled goat anti-mouse Ig subtype antibody (Southern Biotechnology Associates) is then added at optimized concentrations in SDB, and plates are incubated for 1 hour at 37°C. After washing plates 5 times, 100 µl of ABTS substrate (10 ml 0.05 M Citrate (pH 4.0), ~~5 µl~~ 5 µl 30% H₂O₂, ~~50 µl~~ 50 µl 40 mM ABTS) is added. Color is allowed to develop at room temperature for 30 min., and the reaction is stopped by adding 10 µl of 10% SDS. Plates are read at O.D.₄₀₅. Data are analyzed using Softmax Pro Version 2.21 computer software (Molecular Devices, Sunnyvale, CA).

Please replace the paragraph bridging pages 96 and 97, with the following amended paragraph:

Preparation and stimulation of splenocytes for cytokine production. Spleens are harvested from the various groups of mice (n=2-3) and pooled in p60 petri dishes containing about 4 ml RPMI-10 media (RPMI-1640, 10% fetal bovine serum, 50 µg/ml gentamycin). All steps in splenocyte preparations and stimulations are done aseptically. Spleens are minced with curved scissors into fine pieces and then drawn through a 5 cc syringe attached to an 18G needle several times to thoroughly resuspend cells. Cells are then expelled through a nylon mesh strainer into a 50 ml polypropylene tube. Cells are washed with RPMI-10, red blood cells were lysed with ACK lysis buffer

(Sigma, St. Louis, MO), and washed 3 more times with RPMI-10. Cells were then counted by trypan blue exclusion, and resuspended in RPMI-10 containing 80 U/ml rat IL-2 (Sigma, St. Louis, MO) to a final cell concentration of 2×10^7 cells/ml. Cells to be used for intracellular cytokine staining are stimulated in 96-well flat-bottom plates (Becton Dickenson Labware, Lincoln Park, NJ), and cells to be used for cytokine analysis of bulk culture supernatants are stimulated in 96-well U-bottom plates (Becton Dickenson Labware, Lincoln Park, NJ). One hundred microliters of cells are dispensed into wells of a 96-well tissue culture plate for a final concentration of 2×10^6 cells/well. Stimulations are conducted by adding 100 μ l of the appropriate peptide or inactivated influenza virus diluted in RPMI-10. CD8 $^{+}$ T cells are stimulated with either the K d -restricted HA₅₃₃₋₅₄₁ peptide (IYSTVASSL, SEQ ID NO: 1) (Winter, Fields, and Brownlee, 1981) or the K d -restricted NP₁₄₇₋₁₅₅ peptide (TYQRTRALV, SEQ ID NO: 2) Rotzchke et al., 1990). CD4 $^{+}$ T cells are stimulated with inactivated influenza virus (13,000 HAU per well of boiled influenza virus plus 13,000 HAU per well of formalin-inactivated influenza virus) plus anti-CD28 (1 μ g/ml) and anti-CD49d (1 μ g/ml) (Waldrop et al., 1998). Negative control stimulations are done with media alone. Cells are then incubated as described below to detect extracellular cytokines by ELISA or intracellular cytokines by FACS staining.

Please delete the paragraph on page 97, line 3, to page 98, line 6, and replace it with the following paragraph:

Chromium release assay for CTL. CTL responses to influenza HA and NP are measured using procedures well known to those in the art (see, e.g., Current Protocols In Immunology, John E. Coligan et al. (eds), Unit 3, Wiley and Sons, New York, NY 1994, and yearly updates including 2002). The synthetic peptide HA₅₃₃₋₅₄₁IYSTVASSL (SEQ ID NO: 1) (Winter, Fields, and Brownlee, 1981) or NP₁₄₇₋₁₅₅TYQRTRALV (SEQ ID

NO: 2) (Rotzschke et al., 1990) are used as the peptide in the target preparation step. Responder splenocytes from each animal are washed with RPMI-10 and resuspended to a final concentration of 6.3×10^6 cells/ml in RPMI-10 containing 10 U/ml rat IL-2 (Sigma, St. Louis, MO). Stimulator splenocytes are prepared from naïve, syngeneic mice and suspended in RPMI-10 at a concentration of 1×10^7 cells/ml. Mitomycin C is added to a final concentration of 25 µg/ml. Cells are incubated at 37°C/5%CO₂ for 30 minutes and then washed 3 times with RPMI-10. The stimulator cells are then resuspended to a concentration of 2.4×10^6 cells/ml and pulsed with HA peptide at a final concentration of 9×10^{-6} M or with NP peptide at a final concentration of 2×10^{-6} M in RPMI-10 and 10 U/ml IL-2 for 2 hours at 37°C/5% CO₂. The peptide-pulsed stimulator cells (2.4×10^6) and responder cells (6.3×10^6) are then co-incubated in 24-well plates in a volume of 2 ml SM media (RPMI-10, 1 mM non-essential amino acids, 1 mM sodium pyruvate) for 5 days at 37°C/5%CO₂. A chromium-release assay is used to measure the ability of the in vitro stimulated responders (now called effectors) to lyse peptide-pulsed mouse mastocytoma P815 cells (MHC matched, H-2d). P815 cells are labeled with ⁵¹Cr by taking 0.1 ml aliquots of p815 in RPMI-10 and adding 25 µl FBS and 0.1 mCi radiolabeled sodium chromate (NEN, Boston, MA) in 0.2 ml normal saline. Target cells are incubated for 2 hours at 37°C/5%CO₂, washed 3 times with RPMI-10 and resuspended in 15 ml polypropylene tubes containing RPMI-10 plus HA (9×10^{-6} M) or NP (1×10^{-6}) peptide. Targets are incubated for 2 hours at 37°C/5%CO₂. The radiolabeled, peptide-pulsed targets are added to individual wells of a 96-well plate at 5×10^4 cells per well in RPMI-10. Stimulated responder cells from individual immunization groups (now effector cells) are collected, washed 3 times with RPMI-10, and added to individual wells of the 96-well plate containing the target cells for a final volume of 0.2 ml/well. Effector to target ratios are 50:1, 25:1, 12.5:1 and 6.25:1. Cells are incubated for 5 hours at 37°C/5%CO₂ and cell lysis is measured by liquid scintillation

counting of 25 µl aliquots of supernatants. Percent specific lysis of labeled target cells for a given effector cell sample is [100 x (Cr release in sample-spontaneous release sample) / (maximum Cr release-spontaneous release sample)]. Spontaneous chromium release is the amount of radioactive released from targets without the addition of effector cells. Maximum chromium release is the amount of radioactivity released following lysis of target cells after the addition of TritonX-100 to a final concentration of 1%. Spontaneous release should not exceed 15%.

Please delete the paragraph on page 99, lines 22-27, and replace it with the following paragraph:

Tetramers. HA and NP tetramers may be used to quantitate HA- and NP-specific CD8+ T cell responses following HA or NP immunization. Tetramers are prepared essentially as described previously (Flynn et al., 1998). The present example utilizes the H-2K^d MHC class I glycoprotein complexed the synthetic influenza A/PR/8/34 virus peptide HA₅₃₃₋₅₄₁ (IYSTVASSL, SEQ ID NO: 1) (Winter, Fields, and Brownlee, 1981) or NP₁₄₇₋₁₅₅ (TYQRTRALV, SEQ ID NO: 2) (Rotzschke et al., 1990).

Please replace the paragraph at page 100, lines 4-11, with the following amended paragraph:

The circumsporozoite protein (CSP) is a target of ~~this pre-erythrocytic pre-erythrocytic~~ immunity (~~Hoffman et al. Science 252: 520 (1991)~~ (Hoffman et al., Science 252: 520 (1991)). In the *Plasmodium yoelii* (*P. yoelii*) rodent model system, passive transfer *P. yoelii* CSP-specific monoclonal antibodies (Charoenvit et al., *J. Immunol.* 146: 1020 (1991)), as well as adoptive transfer of *P. yoelii* CSP-specific CD8⁺ T cells (Rodrigues et al., *Int. Immunol.* 3: 579 (1991), Weiss et al., *J. Immunol.* 149: 2103 (1992)) and CD4⁺ T cells

(*Renia et al. J Immunol. 150:1471 (1993)*) (*Renia et al., J. Immunol. 150:1471 (1993)*) are protective. Numerous vaccines designed to protect mice against sporozoites by inducing immune responses against the *P. yoelii* CSP have been evaluated.

Please delete the paragraph on page 102, lines 1-5, and replace it with the following paragraph:

CTL responses are measured using procedures well known to those in the art (see, e.g., Current Protocols In Immunology, John E. Coligan et al. (eds), Unit 3, Wiley and Sons, New York, NY 1994, and yearly updates including 2002). The general procedure described elsewhere herein for influenza HA and NP is used except that the cells are pulsed with the synthetic *P. yoelli* CSP peptide (281-296; SYVPSAEQILEFVKQI, SEQ ID NO: 3).

Please replace the paragraph at page 102, lines 20-29, with the following amended paragraph:

Infection and challenge. For a lethal challenge dose, the ID₅₀ of *P. yoelli* sporozoites must be determined prior to experimental challenge. However, for example, it is also initially possible to inject mice intravenously in the tail vein with a dose of about 50 to 100 *P. yoelii* sporozoites (nonlethal non-lethal, strain 17XNL). Forty-two hours after intravenous inoculation, mice are sacrificed and livers are removed. Single cell suspensions of hepatocytes in medium are prepared, and 2x10⁵ hepatocytes are placed into each of 10 wells of a multi-chamber slide. Slides may be dried and frozen at -70°C until analysis. To count the number of schizonts, slides are dried and incubated with NYLS1 before incubating with FITC-labeled goat anti-mouse Ig, and the numbers of liver-stage schizonts in each chamber are counted using fluorescence microscopy.

Please replace the paragraph at page 103, lines 1-4, with the following amended paragraph:

Once it is demonstrated that castration and/or immunization reduces the numbers of infected hepatocytes, blood smears are obtained to determine if immunization ~~protect~~ protects against blood stage infection. Mice can be considered protected if no parasites are found in the blood smears at days 5-14 days post-challenge.

Please replace the paragraph at page 104, lines 3-5, with the following amended paragraph:

Tuberculosis (TB) is a chronic infectious disease of the lung caused by the pathogen *Mycobacterium tuberculosis*, and is one of the most clinically significant infections worldwide. (see, e.g., U.S.P.N. 5,736,524; for review see Bloom and Murray, 1993, Science 257, ~~1055~~ 1055).

Please replace the paragraph at page 106, lines 3-5, with the following amended paragraph:

Plasmid DNA. Suitable Ag85-encoding DNA sequences and vectors have been described previously. See, e.g., U.S.P.N. 5,736,524. Other suitable expression vectors would be readily ascertainably by ~~these~~ those skilled in the art.

Please replace the paragraph at page 106, lines 21-25, with the following amended paragraph:

Enzyme-linked ~~immunosorbant~~ immunosorbent assays. At various time periods pre- and post-immunization, mice from each group are bled, and individual

mouse serum is tested using standard quantitative ELISA to assess anti-Ag85 specific IgG levels in the serum. IgG1 and IgG2a levels may optionally be tested, which are known to correlate with Th2 and Th-type antibody responses, respectively.

Please replace the paragraph at page 110, lines 22-27, with the following amended paragraph:

Any of the RevM10 gene transfer vectors known and described in the art may be used. For example, the retroviral RevM10 vector, pLJ-RevM10 is used to ~~transduce~~ transduce the HSC. The pLJ-RevM10 vector has been shown to enhance T cell engraftment after delivery into HIV-infected individuals (Ranga *et al.*, *Proc. Natl. Acad. Sci. USA* 95:1201 (1998). Other methods of construction and retroviral vectors suitable for the preparation of GM HSC are well known in the art (see, e.g., Bonyhadi *et al.*, *J. Virol.* 71:4707 (1997)).

Please replace the paragraph bridging pages 112 and 113, with the following amended paragraph:

In this example, human cord blood (CB) HSC are collected and processed using techniques well known to those skilled in the art (see, e.g., DiGusto *et al.*, *Blood*, 87:1261 (1997), Bonyhadi *et al.*, *J. Virol.* 71:4707 (1997)). A portion of each CB sample is HLA ~~phenotyped~~ phenotyped, and the CD34⁺ donor cells are purified from the donor blood (or bone marrow), such as by using a flow cytometer or immunomagnetic beading, essentially as described above. Donor-derived HSC are identified by flow cytometry as being CD34⁺.

Please replace the paragraph at page 113, lines 18-20, with the following amended paragraph:

In this example, CD34⁺-enriched HSC undergo transfection by a linearized RevM10 plasmid utilizing particle-mediated (~~"gene gun" transfer~~) ("gene gun") transfer essentially as described in Woffendin *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:2889 (1996).